CAR-Based Cell Therapies for Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation, systemic inflammation, and multi-organ damage. Despite advances in immunosuppressive therapies and biologics targeting B cells, many patients remain refractory to treatment or experience relapse. The emergence of chimeric antigen receptor (CAR)-based cell therapies, initially developed for hematological malignancies, has opened new therapeutic avenues for SLE. This article comprehensively reviews the application, clinical outcomes, challenges, and future directions of CAR-based therapies in SLE, as highlighted in recent research.
Pathogenesis and Current Management of SLE
SLE arises from a combination of genetic, epigenetic, environmental, and hormonal factors, leading to loss of immune tolerance, autoantibody production, and tissue damage. Key pathogenic features include dysregulated B and T cell interactions, type I interferon hyperactivity, and immune complex deposition. Conventional treatments such as glucocorticoids, antimalarials (e.g., hydroxychloroquine), and immunosuppressive agents (e.g., mycophenolate mofetil) lack specificity, often causing systemic immunosuppression and adverse effects.
B cell-targeted biologics, including rituximab (anti-CD20) and belimumab (anti-BAFF/BLyS), have improved outcomes but face limitations. Rituximab, while effective in diseases like rheumatoid arthritis, showed mixed results in SLE trials (e.g., EXPLORER and LUNAR), with incomplete B cell depletion and relapse post-treatment. Belimumab, a BAFF inhibitor, reduces disease activity but does not eliminate autoreactive B cells. These limitations underscore the need for therapies capable of deeper, sustained B cell depletion.
CAR T Cell Therapy: Mechanism and Preclinical Insights
CAR T cells are engineered T cells expressing synthetic receptors that combine antigen-binding domains (e.g., single-chain variable fragments, scFv) with intracellular signaling domains (e.g., CD3ζ, costimulatory molecules like CD28 or 4-1BB). Upon antigen recognition, CAR T cells activate, proliferate, and mediate cytotoxicity against target cells. In oncology, CAR T cells targeting CD19 or BCMA have achieved durable remissions in B cell malignancies.
Preclinical studies in murine lupus models demonstrated that CD19-targeted CAR T cells induce profound B cell depletion, reduce autoantibodies, and prevent disease progression. For example, adoptive transfer of CD19 CAR T cells in lupus-prone mice resulted in sustained remission, normalized serological markers, and reduced renal pathology, supporting translational potential in SLE.
Clinical Applications in SLE: Breakthroughs and Outcomes
Recent clinical trials have validated CAR T cell therapy in refractory SLE. A landmark case study reported complete remission in a 20-year-old patient with severe SLE (renal, hematologic, and dermatologic involvement) after a single infusion of CD19-directed CAR T cells (1.1 × 10⁶ cells/kg). B cell aplasia occurred within 5 days, accompanied by normalization of anti-dsDNA antibodies, complement levels, and proteinuria. All immunosuppressive drugs were discontinued, and remission persisted for 18 months without adverse events.
Subsequent trials expanded to eight SLE patients (median age 24 years, SLEDAI-2K score 13 at baseline) receiving CD19 CAR T cells. Key findings included:
- Rapid B cell depletion: CD19+ B cells undetectable in peripheral blood by day 5.9 (mean) and remained absent for 112 days.
- Sustained remission: All patients achieved lupus low disease activity state (LLDAS) and DORIS criteria by 6 months, with SLEDAI-2K scores dropping to 0.
- Immune reconstitution: B cell reconstitution at 6–12 months revealed naïve B cell predominance, with reduced memory B cells and plasmabasts, suggesting immune reset.
- Safety: No severe cytokine release syndrome (CRS) or neurotoxicity (ICANS) occurred; five patients had grade 1 CRS managed with tocilizumab.
A phase I trial of BCMA-CD19 compound CAR (cCAR) T cells in 13 SLE/LN patients demonstrated similar efficacy. Nine patients achieved DORIS remission, and 12 met LLDAS by 6 months. Renal function improved in LN patients, with autoantibody clearance and B cell receptor repertoire reset. Adverse events were mild (grade 1 CRS), supporting cCAR safety.
Challenges in CAR-Based Therapies for SLE
Safety Considerations
While CAR T therapy in SLE has shown favorable safety compared to oncology, risks include CRS, infections, and hematotoxicity. CRS, driven by cytokine surges (IL-6, IFN-γ), manifests as fever, hypotension, or organ dysfunction. In SLE trials, CRS was mild (grade 1) and manageable. Prolonged B cell aplasia (mean 112 days) raises infection risks, though immunoglobulin levels remained stable, and vaccine responses were preserved.
CAR T Cell Dysfunction
T cell exhaustion, driven by chronic antigen exposure or immunosuppressive microenvironments, may limit efficacy. In SLE, shorter B cell aplasia (~100 days) versus hematologic malignancies suggests potential CAR T cell dysfunction. Strategies to enhance persistence, such as optimizing costimulatory domains (4-1BB vs. CD28) or using “armored” CARs with cytokine support, are under investigation.
Patient and Target Selection
Optimal candidates are early-stage patients without irreversible organ damage. Current CAR products (CD19, BCMA) target antibody-producing cells but may not address T cell-driven pathology or interferon pathways. Dual-target CARs (e.g., CD19/CD20, BCMA/BAFF) aim to broaden efficacy. Biomarkers to identify autoreactive B cell clones or predict relapse are critical for personalized therapy.
Innovations in CAR-Based Therapies
Universal CAR T Cells
Allogeneic CAR T cells from healthy donors or iPSCs offer “off-the-shelf” availability, reduced costs, and faster manufacturing. Early trials in SLE/SSc are testing CD19 allogeneic CAR T cells with TCR knockout to prevent graft-versus-host disease (GvHD). Challenges include shorter persistence and host immune rejection.
Chimeric Autoantibody Receptor T Cells (CAAR-T)
CAAR-T cells replace scFv with autoantigens (e.g., dsDNA, Ro-52) to selectively eliminate autoreactive B cells. Preclinical success in pemphigus and myasthenia gravis supports CAAR-T potential in SLE, preserving normal immunity.
CAR Regulatory T Cells (CAR-Tregs)
CAR-Tregs engineered to express autoantigen-specific receptors (e.g., anti-CD19) may restore immune tolerance. Preclinical studies in diabetes and colitis show reduced inflammation via IL-10/TGF-β secretion. Challenges include ensuring stability and tissue homing.
Conclusion
CAR-based cell therapies represent a paradigm shift in SLE treatment, offering durable remission and immune reset beyond conventional therapies. Clinical trials demonstrate rapid B cell depletion, serological normalization, and steroid-free remission with manageable toxicity. Innovations like universal CARs, CAAR-T, and CAR-Tregs aim to enhance precision and safety. However, challenges in long-term efficacy, patient selection, and cost necessitate further research. Collaborative efforts to optimize CAR design, validate biomarkers, and conduct large-scale trials will be pivotal in realizing the curative potential of CAR-based therapies for SLE.
doi.org/10.1097/CM9.0000000000003406
Was this helpful?
0 / 0